Planview Named a Leader in the April 2023 Gartner® Magic Quadrant™ for Strategic Portfolio Management for Second Consecutive Year
Planview, the leading platform for connected work from portfolio planning to delivery, announced today that it was named a Leader in the April 2023 Gartner Magic Quadrant for Strategic Portfolio Management 1 for the second year in a row, based on its Completeness of Vision and Ability to Execute.
Download a complimentary copy of the April 2023 Gartner Magic Quadrant for Strategic Portfolio Management report.
“At Planview, our goal is to unleash the power of connected work for organizations worldwide. For many companies, this means successfully executing their organization’s transformation and cross-functional strategic initiatives – especially in times of significant change,” said Louise K. Allen, Chief Product Officer at Planview. “To make this shift, leaders must eliminate the disconnects between strategy and delivery that slow down response times and make trade-off decisions and reprioritization difficult. Our solution helps companies to stay ahead of the curve with scenario planning and prioritization, driving business results in any environment.”
According to Gartner, “By 2025, 70% of digital investments will fail to deliver the expected business outcomes due to the absence of a strategic portfolio management (SPM) approach."
Planview’s SPM solution enables organizations to adapt to disruption and drive success in strategy execution and transformation by improving speed-to-value and market responsiveness, increase confidence in strategic investments, and unlock organizational capacity for priority initiatives. By creating business agility and reducing the disconnects between strategy, teams, and outcomes, organizations can adapt to disruption and deliver business success faster and with more confidence.
Planview was also recognized in the Gartner companion research to the Magic Quadrant, the Critical Capabilities for Strategic Portfolio Management2. This report evaluates vendors on a set of product features and capabilities and discusses how those apply to important Use Cases. Planview received the highest score in three out of three Use Cases: Strategy Execution Management, Enterprise Program and Portfolio Management, and Integrated IT Portfolio Analysis.
To learn more about Planview’s SPM solution, go here.
1 Gartner, Magic Quadrant for Strategic Portfolio Management by Anthony Henderson, Daniel Stang, John Spaeth, Shailesh Muvera, and Woojin Choi, April 25, 2023.
2 Gartner, Critical Capabilities for Strategic Portfolio Management by Anthony Henderson, Daniel Stang, John Spaeth, Shailesh Muvera, Woojin Choi, April 26, 2023.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
GARTNER is a registered trademark and service mark of Gartner and Magic Quadrant is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.
About Planview
Planview has one mission: to build the future of connected work, from ideas to impact. Planview helps organizations accelerate the achievement of what matters most, supporting our customers from need to speed, from passion to progress, and from overhead to optimization. Our connected platform of solutions underpins the business and digital transformations of more than 4,500 customers globally, including 59 of the Fortune 100. Planview empowers enterprises to improve time-to-market and predictability, increase efficiency to unlock capacity, and ensure their most strategic initiatives deliver the desired business outcomes. Learn more about our portfolio at planview.com, and connect with us on LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230428005379/en/
Contact information
Media Relations for Planview
Natalie Reina
Director of Corp Comms
956-878-9176
natalie.reina@planview.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Inca Arrives to USA, a Strong Outlook for Peru Tourism Recovery27.5.2023 18:00:00 EEST | Press release
The Inca emperor walks the streets of New York City while his retinue dances tirelessly along the way, garnering the attention of the passers-by who stopped to stare and take video of the captivating scene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230526005330/en/ Peruvian actors from Cusco promoting the Inti Raymi 2023 in New York City, as tourism in Peru is once more on the rise. (Photo: PROMPERÚ). This performance was displayed by 30 actors from Cusco, Peru, as a promotional strategy to get Peru back in the news and in front of potential visitors in a positive way. The upcoming Inti Raymi (Festival of the Sun), a thousand-year-old ritual worshiping the Sun God and asking him to make the days longer, was promoted in the Big Apple in order to put the most notable celebration of Cusco’s calendar in the international spotlight. Inti Raymi honors the Sun each June 24th and celebrates the winter solstice of the Southern H
10th Annual World Patient Safety, Science & Technology Summit Is Sold Out!27.5.2023 07:10:00 EEST | Press release
Registration for the 10th Annual Patient Safety, Science & Technology Summit is now closed. This in-person Summit marks the nonprofit’s 10th anniversary and will be held in Newport Beach, California, from June 1 to 2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230526005374/en/ Annual World Patient Safety, Science & Technology Summit (Photo: Business Wire) “We are very encouraged at the response we received for our first in-person Summit since Covid-19,” said Dr. Michael Ramsay, CEO, Patient Safety Movement Foundation. “Many organizations felt a significant setback caused by the Covid-19 pandemic, but I believe this Summit will be the perfect way to get back on course. We have an incredible program designed for our 10th anniversary, with renowned speakers from around the world, including President Bill Clinton, Dr. Don Berwick, Dr. Neelam Dhingra, Sir Liam Donaldson, Dr. Peter Pronovost, Dr. Jannicke Mellin-Olsen, Dr. Mic
Sims Limited Achieves Climate Leaders Asia-Pacific 2023 Recognition27.5.2023 05:49:00 EEST | Press release
Sims Limited (ASX: SGM), a global leader in sustainability and an enabler of the circular economy, has been named to the Financial Times 2023 Asia-Pacific Climate Leaders list for the second time. Sims Limited was one of 275 companies on the prestigious list, which highlights companies that have made genuine greenhouse gas emissions reductions relative to their revenues over a five-year period. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230526005346/en/ FT-Statista Climate Leaders 2023 logo (Graphic: Business Wire) For the second consecutive year, Financial Times and Statista examined publicly available disclosures of more than 2,000 companies in the Asia-Pacific region to compile the Climate Leaders Asia-Pacific list. The list is comprised of companies that achieved the greatest reduction in their core emissions intensity between 2016 and 2021 – that is, their Scope 1 and 2 greenhouse gas emissions in relation to revenu
Skyflow Radically Simplifies Data Residency26.5.2023 18:00:00 EEST | Press release
Today Skyflow, the data privacy vault company, announced new data residency capabilities including Asia-Pacific instances in Japan, Indonesia, India, and Bahrain, and an expansion of its footprint in EMEA and North America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230526005072/en/ (Graphic: Business Wire) With Skyflow, companies that store sensitive customer data can meet regulatory requirements for localized storage, provable and auditable data protection, and governance – simply by leveraging Skyflow’s global vault infrastructure. This enables global expansion to reach new customers in new markets, while minimizing complexity and cost. For example, SaaS ISVs can scale and sell their product in both EMEA and APAC without adding instances. Replicating Instances is Expensive and Slow Today, companies that want to expand internationally face a technically complex and expensive proposition: replicate all of your cloud inf
FORE Biotherapeutics to Present Promising New Data from Phase 1/2a Trial Evaluating Plixorafenib (FORE8394) in Patients With BRAF-Altered Advanced Solid and Central Nervous System Tumors at ASCO 202326.5.2023 16:00:00 EEST | Press release
FORE Biotherapeutics today announced new clinical data from the Phase 1/2a clinical trial for plixorafenib (FORE8394), a novel, investigational, small-molecule, next-generation, orally available selective inhibitor of BRAF alterations. The results demonstrate promising single-agent activity against BRAF-altered tumors, including primary central nervous system (CNS) tumors, and will be featured in presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 2-6, 2023, in Chicago, IL. “The updated data from our Phase 1/2a study further reinforces plixorafenib’s differentiated clinical profile,” said Stacie Shepherd, MD, PhD, and Chief Medical Officer of FORE. “Plixorafenib has demonstrated both promising antitumor activity with durable responses and favorable tolerability as a single agent in patients with advanced BRAF-altered tumors. Notably, plixorafenib has a striking safety profile as compared to the currently approved BRAF/MEK and investiga
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom